Andrew Lawrence Feldhaus

This inventor holds 28 USPTO granted patents and 5 published patent applications and 2 EPO patents, primarily in Antibody Therapeutics. Top assignees: Alderbio Holdings LLC, Targeted Genetics Corporation, Zymogenetics, Inc.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Lawrence Feldhaus. Retrieved from https://idiyas.com/inventor/andrew-lawrence-feldhaus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 5)

% Patents Active = 67.9

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 3.5

ph-index = 10

Forward Citations = 260(Granted Patents)

Location History:

Lynwood, WA (US) (1999 - 2003)
Lynnwood, WA (US) (1998 - 2022)

Company Filing History:

11 out of 98

Alderbio Holdings LLC

patents

5 out of 20

Targeted Genetics Corporation

Alder Biopharmaceuticals, Inc.

patents

6. 1 out of 1

Targeted Genetics Corporation and Immunex

patent

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Anti-ACTH Antibodies

Anti-PCSK9 Antibodies

Therapeutic Antibodies

Humanized Antibodies

Oral Mucositis Treatment

Transcriptionally-Activated AAV

Hybrid Genes

Cystatin Proteins

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428475 - Humanized anti-ACTH antibodies and use thereof (2025-09-30),

2. 12351627 - Anti-ACTH antibodies and use thereof (2025-07-08),

3. 11427631 - Anti-ACTH antibodies and use thereof (2022-08-30),

4. 11117960 - Humanized anti-ACTH antibodies and use thereof (2021-09-14),

5. 10550180 - Anti-ACTH antibodies and use thereof (2020-02-04),

6. 10544214 - Humanized anti-ACTH antibodies and use thereof (2020-01-28),

7. 10259885 - Anti-PCSK9 antibodies and use thereof (2019-04-16),

8. 10100108 - Antibodies to HGF and compositions containing (2018-10-16),

9. 10047157 - Humanized anti-ACTH antibodies and use thereof (2018-08-14),

10. 9957321 - Anti-IL-6 antibodies for the treatment of oral mucositis (2018-05-01),

11. 9783603 - Therapeutic use of antibodies to HGF (2017-10-10),

12. 9732150 - Therapeutic use of antibodies to HGF (2017-08-15),

13. 9688754 - Anti-ACTH antibodies and use thereof (2017-06-27),

14. 9481725 - Antibodies to HGF and compositions containing (2016-11-01),

15. 9255154 - Anti-PCSK9 antibodies and use thereof (2016-02-09),

Title: Andrew Lawrence Feldhaus: Innovator in Antibody Development

Introduction

Andrew Lawrence Feldhaus is a prominent inventor based in Lynnwood, Washington, with a remarkable portfolio that includes 26 patents. His work primarily focuses on innovative antibody technologies that have significant implications in the medical field. Through his continued research and development, he has contributed to the advancement of therapies for various diseases.

Latest Patents

Among Feldhaus's notable patents are innovative developments concerning anti-ACTH antibodies and their applications. One patent details antibodies and fragments with binding specificity for adrenocorticotropic hormone (ACTH). This invention emphasizes not only the antibodies themselves but also methods of producing them and their potential conjugates. Furthermore, the patent outlines their use in diagnosing and treating numerous conditions associated with ACTH, such as Cushing's Disease, obesity, diabetes, and cognitive disorders.

Another recent patent expands on this concept, introducing humanized anti-ACTH antibodies and their binding fragments. It aims to enhance diagnosis, assessment, prevention, and treatment of various ACTH-related disorders, showcasing the versatility and therapeutic potential of these antibodies in addressing critical health issues.

Career Highlights

Throughout his career, Feldhaus has made significant contributions while working for various organizations. He notably served at Alderbio Holdings and Zymogenetics, where he collaborated on cutting-edge projects within the biotechnology sector. His expertise in antibody development has set the foundation for advancements in medical research and therapeutic applications.

Collaborations

Feldhaus has also worked alongside notable colleagues, including Leon F. Garcia-Martinez and Benjamin H. Dutzar. Their joint efforts reflect the collaborative spirit necessary for scientific innovation, helping further the field of biomedicine.

Conclusion

Andrew Lawrence Feldhaus stands out as an influential inventor in the realm of antibody technologies. His 26 patents illustrate his commitment to addressing critical healthcare challenges through innovative solutions. The significant applications of his work in diagnosing and treating various diseases underscore the impact of his contributions to medical science and biotechnology.

Profile summary based on public USPTO records.